Patient-associated risk factors for severe anemia in patients with advanced ovarian or breast cancer receiving olaparib monotherapy: A multicenter retrospective study

Autor: Ryota Tashiro, Hitoshi Kawazoe, Kanako Mamishin, Keisuke Seto, Ryoko Udagawa, Yoshimasa Saito, Hironobu Hashimoto, Tatsunori Shimoi, Kan Yonemori, Masahito Yonemura, Hiroyuki Terakado, Toshikatsu Kawasaki, Tetsuya Furukawa, Tomonori Nakamura

Publikováno v: Frontiers in Oncology, Vol 12 (2022)

BackgroundOlaparib-induced anemia is a frequently occurring complication in patients with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer and is associated with a marked deterioration in patients’ health-related quality

Externí odkaz: https://doaj.org/article/4a7f9c552d79479c93a8989899915f64

Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response

Autor: Elisena Franzese, Sara Centonze, Anna Diana, Angela Lombardi, Francesca Carlino, Luigi Pio Guerrera, Ferdinando De Vita, Michele Caraglia, Sandro Pignata, Fortunato Ciardiello, Michele Orditura

Publikováno v: Frontiers in Oncology, Vol 9 (2019)

Objective: We assessed the genomic profile of four representative BRCA-mutated ovarian cancer (OC) patients treated with olaparib to investigate the relationship between intratumor heterogeneity and response to olaparib treatment. The main aim is to

Externí odkaz: https://doaj.org/article/a4cb591f5ba34c5987d5dc70f6b04451

Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response

Autor: A. Diana, Angela Lombardi, Elisena Franzese, Michele Orditura, Fortunato Ciardiello, Sara Centonze, Sandro Pignata, Ferdinando De Vita, Michele Caraglia, Luigi Pio Guerrera, Francesca Carlino

Publikováno v: Frontiers in Oncology
Frontiers in Oncology, Vol 9 (2019)

Objective: We assessed the genomic profile of four representative BRCA-mutated ovarian cancer (OC) patients treated with olaparib to investigate the relationship between intratumor heterogeneity and response to olaparib treatment. The main aim is to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3abd9ed863ac8234c90f0904239e3ab
http://europepmc.org/articles/PMC6895028

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials

Autor: de Haan, Rosemarie, Pluim, Dick, van Triest, Baukelien, van den Heuvel, Michel, Peulen, Heike, van Berlo, Damien, George, Jay, Verheij, Marcel, Schellens, Jan H M, Vens, Conchita, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology

Publikováno v: Radiotherapy and Oncology, 126(3), 443-449. Elsevier Ireland Ltd
Radiotherapy and Oncology, 126, 443-449
de Haan, R, Pluim, D, van Triest, B, van den Heuvel, M, Peulen, H, van Berlo, D, George, J, Verheij, M, Schellens, J H M & Vens, C 2018, ' Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials ', Radiotherapy and Oncology, vol. 126, no. 3, pp. 443-449 . https://doi.org/10.1016/j.radonc.2017.10.017
Radiotherapy and Oncology, 126, 3, pp. 443-449
Radiotherapy and Oncology, 126(3), 443. Elsevier Ireland Ltd.

Item does not contain fulltext BACKGROUND: PARP inhibitors are currently evaluated in combination with radiotherapy and/or chemotherapy. As sensitizers, PARP inhibitors are active at very low concentrations therefore requiring highly sensitive pharma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c045aa083fff7b40e46dd18b05edde0e
https://hdl.handle.net/1874/375266